Investor Presentaiton
CRO Phase III Products Portfolio
29
NDA Filing
Year (E)
Indication
Region
Type I,II
2018
Diabetes
2018
Advanced
Hepatocellular
Carcinoma,
Myelofibrosis,
Autoimmune disease
2018
Prostate Cancer
Familial Adenomatous
2019
Polysis
Remarks
Intermediate project made both in
US/EU Changshu & Taiwan sites. Expected revenue
of several million USD per year after launch
CN
API project made in Changshu site. CFDA
granted accelerated review under its
category 1.1 innovative drug. Anticipated
launch in 2019 with demand in tons
Started process validation. Anticipated
US EU launch in 2019 and revenue of several
million USD per year
API project made both in Taiwan &
US/EU Changshu sites. Anticipated launch in 2020
with demand in tons to tens tons
ScinoPharmView entire presentation